HOME / Notice / News / EN
On July 4, NKCL Bio Group Inc. (CEO Shin, Donghwa) and I Partners Group (CEO Jung, Yiho) announced that they had signed an MOU for innovative technology in the medical field. I Partners Group is a specialized company that supplies programs that combine in various areas; such as, medical device, healt...
Dong-hwa Shin, chairman of NKCL Bio Group Inc.(NKCL Bio Group), was honored with the Grand Prize in the NK cell therapy category of the ‘2022 Consumer Selected Quality Satisfaction Award’. Celebrating its 13th anniversary this year, the '2022 Consumer Quality Satisfaction Award' is an award ceremon...
On June 28, the 'JTC Group of Companies ' visited NKCL Bio Group. NKCL Biogroup has explained its technological competitiveness of NK cell therapy, which is spotlighted as a next-generation anticancer treatment, to the 'JTC Group of Companies', and shared the future vision regarding the growth of imm...
On the 20th, the Cambodian economic delegation, the Reachsey Association, visiting Korea at the moment, visited NKCL Bio Group Inc. and announced that they discussed ways to cooperate in the bio industry between the two countries. The Cambodian economic delegation to Korea, the Reachsey Association, ...
NKCL Bio Group Inc. (Chairman Dong-Hwa Shin, hereinafter referred to as NKCL) announced that it had acquired a ‘T-4’ grade, an excellent company certification at Technology Credit Bureau(TCB) by NICE evaluation information, a nationally accredited technology credit rating agency. The Tech Credit Bu...